News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
